Загрузка...
Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice
The development of inhibitory antibodies against factor VIII (FVIII) is a major challenge in hemophilia A (HA) therapy. Such antibodies develop in nearly 30% of patients receiving replacement FVIII, abrogating therapeutic efficacy. This work evaluated whether B-domain deleted FVIII encapsulated in p...
Сохранить в:
| Опубликовано в: : | Biopharm Drug Dispos |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5125252/ https://ncbi.nlm.nih.gov/pubmed/27418232 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/bdd.2023 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|